NRX Pharmaceuticals, Inc.

Thank you. ¶¶ We'll be right back. Thank you. Thank you. We'll be right back. Thank you.

Good morning, ladies and gentlemen, and welcome to the NRX Pharmaceuticals Q4 2025 Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call has been recorded on Tuesday, March 24, 2026. I would now like to turn the conference over to Michael Abrams, CFO. Please go ahead.

Thank you, Joelle, and welcome, everyone. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under the United States Federal Securities Laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause results to differ From statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release issued today and in the company's Form 10-K, which may be assessed from the Investors page on the NRX Pharmaceuticals website. Joining me on the call today is Dr. Jonathan Javitt, our founder, chairman, and CEO. Dr. Javitt will provide an overview of our company's progress as reported yesterday on Form 10-K, following which I will review our financial results. Following their prepared remarks, these prepared remarks, we will address investor questions. I will now turn the call over to Jonathan.